PD-1 Inhibitor Plus Chemotherapy With or Without Radiotherapy in Patients With Metastatic Esophageal Cancer
Status:
Recruiting
Trial end date:
2029-08-28
Target enrollment:
Participant gender:
Summary
The treatment efficacy for stage IVb esophageal cancer has been improved through chemotherapy
combined with immunotherapy recently.
On this basis, the investigators intend to conduct a prospective, multicenter phase III
clinical trial to assess whether radiotherapy with concurrent chemotherapy and immunotherapy
could further improve the survival of patients with metastatic esophageal cancer.
Accompanied tissue samples, blood samples and urine samples will be analyzed by molecular
biological detection (Including Whole Exome Sequencing and proteomics) to explore potential
biomarkers for predicting outcomes, efficacy and toxicity.
Phase:
Phase 3
Details
Lead Sponsor:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Collaborators:
Affiliated Hospital of North Sichuan Medical College Anyang Tumor Hospital Beijing Cancer Prevention & Treatment Society Changzhou Cancer Hospital of Soochow University First Affiliated Hospital Xi'an Jiaotong University Fujian Cancer Hospital Hebei Medical University Fourth Hospital Henan Cancer Hospital Peking University Cancer Hospital & Institute Second Affiliated Hospital of Xi'an Jiaotong University Sichuan Cancer Hospital and Research Institute Tengzhou Central People's Hospital The First Affiliated Hospital of Xiamen University The First Affiliated Hospital of Zhengzhou University The First Affiliated Hospital with Nanjing Medical University Tianjin Medical University Cancer Institute and Hospital